rs11720203 - LINC02016
Magnitude 2.2 · 1 study on file
Reported associations
-
Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors - Unknown journal (n.d.) · Unknown authors · PubMed 39543288
ABSTRACT: Tinnitus is a common sensorineural complication that can occur de novo or after cancer treatments involving cisplatin or radiotherapy. Considering the heterogeneous etiology and pathophysiology of tinnitus, the extent to which shared genetic risk factors contribute to de novo tinnitus and cancer treatment-induced tinnitus is not clear. Here we report a GWAS for de novo tinnitus using the UK Biobank cohort with nine loci showing significantly associated variants (p < 5 × 10-8). To our knowledge, significant associations in four of these loci are novel, represented by rs7336872, rs115125870, rs1532898 and rs2537, with UBAC2, NUDT9, TGM4 and MPP2 as their nearest protein coding genes, respectively. Through quantitative comparison of results from GWAS of de novo tinnitus w
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Lifestyle
-
Hearing protection in high-noise environments Moderate
Genetic predisposition to tinnitus suggests heightened sensitivity to noise exposure
Wear hearing protection in environments exceeding 85dB; limit recreational loud sound exposure
- GWAS_CATALOG:39543288
Screening
-
Baseline and periodic hearing assessment Moderate
Genetic variant associated with significantly increased tinnitus risk in large GWAS
Obtain baseline audiometry; consider repeat screening every 2-3 years
- GWAS_CATALOG:39543288